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Abstract
Macrolides, a class of antimicrobials isolated from Streptomycetes more than 50 years ago, are used
extensively to treat sinopulmonary infections in humans. In addition, a growing body of
experimental and clinical evidence indicates that long-term (years), low (sub-antimicrobial)-dose
14- and 15-membered ring macrolide antibiotics, such as erythromycin, clarithromycin,
roxithromycin and azithromycin, express immunomodulatory and tissue reparative effects that are
distinct from their anti-infective properties. These salutary effects are operative in various lung
disorders, including diffuse panbronchiolitis, cystic fibrosis, persistent chronic rhinosinusitis, nasal
polyposis, bronchiectasis, asthma and cryptogenic organizing pneumonia.
The purpose of this overview is to outline the immunomodulatory effects of macrolide antibiotics
in patients with asthma.
Macrolide antibiotics and asthma pathogenesis
Asthma is a chronic inflammatory disease characterized
by airway narrowing. There are three distinct components
of reduction in airway caliber: secretions, smooth muscle
contraction and airway wall thickening. While pathoge-
netic changes that bring about airway narrowing may be
heterogeneous, it is generally accepted that inflammatory
cell infiltration with secretion of pro-inflammatory
cytokines plays a major role in pathogenesis of asthma.
The major inflammatory cells that are involved in this
process are type 2 helper T (Th2) cells, eosinophils and
mast cells.
Upon stimulation, Th2 cells elaborate various cytokines
(IL-4, IL-5, IL-13 and GM-CSF in particular) that stimulate
the plasma cells to switch to specific IgE production and
induce myeloid differentiation. IgE bind to mast cells that
result in secretion of preformed mediators of bronchoc-
onstriction and glandular secretion (histamine, leukot-
rienes and kallikrein) as well as secretion of cytokines (IL-
4 and IL-5), which increase eosinophil chemotaxis and
Th2 and mast cell proliferation (positive feedback). When
stimulated by IgE, eosinophils release a number of com-
pounds cytotoxic to airway epithelium such as eosinophil
cationic protein (ECP) as well as IL-8, a chemotactic factor
for eosinophils and neutrophils. Neutrophilic inflamma-
tion becomes more pronounced and is related to airflow
obstruction particularly in the airways of chronic asthmat-
ics.
The airway epithelium may also play an important role in
initiation and maintenance of the inflammatory response
through secretion of chemokines such as Regulated on
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(RANTES) that attracts eosinophils, basophils and lym-
phocytes to the airway. Airway epithelium also elaborates
nitric oxide (NO), which is thought to suppress Th1 cells
thereby augmenting Th2 cell induced inflammation.
Through a process termed airway remodeling, these acute
inflammatory events may lead to cellular proliferation,
smooth muscle hypertrophy and hyperplasia, and colla-
gen deposition below the basement membrane. The pre-
cise relationship of acute inflammatory cascade to airway
remodeling and its modification by host and environ-
mental factors are under investigation.
The 14- and 15-membered ring macrolide antibiotics may
interfere with cytokine production and inflammatory cell
metabolism relevant to asthma pathogenesis outlined
above at various levels. The hydrophobic nature of the 14-
or 15-membered lactone ring and hydrophilic nature of
both sugar moieties may lead to formation of drug
micelles and promote the interaction of macrolide antibi-
otics with phospholipids in the plasma and intracellular
organellar membranes. This, in turn, may alter the bio-
physical properties of the effector inflammatory cell mem-
brane thereby interfering with the regulation of
intracellular metabolic and transcriptional pathways
involved in the inflammatory cascade, such as elaboration
of reactive oxygen species by NADPH oxidase and release
of myeloperoxidase and elastase in neutrophils. This so-
called membrane stabilizing effect may in part account for
anti-inflammatory actions of macrolide antibiotics [1].
Macrolide antibiotics affect metabolism of various
inflammatory mediators. Administration of erythromycin
to rats for 3 months reduced production of cytokine
induced neutrophil chemoattractant (CINC)-1, rat coun-
terpart for human interleukin-8, from rat alveolar macro-
phages [2].
Kohayama et al [3] showed a reduction in interleukin-8
release from eosinophils from atopic individuals who
were treated with 14-membered ring macrolide antibiot-
ics. In an elegant study probing mechanism of action of
this effect, Abe et al [4] investigated the effects of clarithro-
mycin on interleukin-8 gene expression and protein levels
in human bronchial epithelial cell line BET-1A. Clarithro-
mycin inhibited IL-8 gene expression in a dose and time
dependent manner and the action was mediated by sup-
pression of activated protein-1 binding and nuclear factor
(NF)-κB sites. Eosinophil apoptosis is facilitated by mac-
rolides [5]. Erythromycin inhibits RANTES secretion from
human fibroblasts in vitro [6]. Macrolides also may
reduce GM-CSF secretion from human monocytes and
lung fibroblasts [7,8].
Oxidative burst in neutrophils is inhibited by roxithromy-
cin [9]. Shimizu et al [10] showed reduction in expression
of messenger RNA for the gene responsible for mucin pro-
duction (MUC5AC) in nasal epithelium of rats adminis-
tered clarithromycin, inferring a direct inhibitory effect on
mucus secretion. Roxithromycin inhibits mast cell inflam-
matory cytokine production (TNF-alpha) in a dose
dependent fashion [11]. In a study of 15 patients with
mild to moderate asthma, Chu et al demonstrated reduc-
tion of airway edema on endobronchial biopsies, as
inferred by relative increase in vascularity, following a 6-
week treatment with clarithromycin [12]. Although mech-
anism of such an effect was unclear, the reduction of
edema was significantly more in asthmatic patients who
tested positive for Mycoplasma pneumoniae, suggesting
an antimicrobial mechanism of action. Finally, NO gener-
ation in mice in response to lipopolysaccharide stimula-
tion is suppressed significantly after 4 weeks of oral
macrolide antibiotic administration, suggesting that anti-
inflammatory effects may, in part be mediated by the NO
pathway [13].
Macrolide antibiotics and asthma therapy
Macrolide antibiotics, particularly troleandomycin and
erythromycin, decrease corticosteroid requirements in
patients with prednisolone-dependent asthma. Spector
and his colleagues [14] conducted a double-blind crosso-
ver trial comparing troleandomycin to placebo in 74 cor-
ticosteroid-dependent patients with severe asthma and
chronic bronchitis. Two-thirds of patients showed marked
improvement in sputum production, pulmonary function
measurements, need for bronchodilators, and subjective
evaluation. Much of this effect, however, was attributed to
troleandomycin-induced inhibition of methylpred-
nisolone and theophylline metabolism by the hepatic
cytochrome P-450 complex [15]. Troleandomycin was
later discontinued because of its intolerable adverse
effects, particularly osteoporosis, associated with prolon-
gation of methylprednisolone half-life and long-term
elaboration of prednisone in vivo.
Low-dose, long-term macrolide antibiotics therapy may
have effects beyond their corticosteroid-sparing action in
asthma. To this end, macrolide antibiotics inhibit lym-
phocyte proliferation in response to phytohemagglutinin,
decrease neutrophil accumulation via decrease in chemo-
tactic activity, decrease mucus secretion and decrease con-
traction of isolated bronchial tissue [16]. Open label
studies with troleandomycin in methylprednisolone-
dependent patients with asthma have demonstrated
greater reduction in methylprednisolone doses than
would have been predicted by inhibition of methylpred-
nisolone metabolism in the liver [17]. Gotfried and his
colleagues [18] showed a significant improvement in pul-
monary function test results and in quality of life meas-
ures in prednisone dependent patients with asthma
following a six-week course of clarithromycin without any
change of prednisone requirements. In a small case seriesClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/4
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of patients administered clarithromycin for one year, two
of three prednisone dependent patients were able to dis-
continue prednisone altogether [19].
Macrolide antibiotics are efficacious in patients with
asthma not treated with corticosteroids by reducing air-
way hyperreactivity and eosinophilic inflammation. A 10-
week course of low-dose erythromycin was associated
with significant decrease in bronchial hyperresponsive-
ness to histamine challenge, expressed as PC20, in
patients with asthma [20]. In a double blind, placebo-
controlled crossover trial, Amayasu et al [21] treated 17
adults with mild to moderate asthma who were clinically
stable with low-dose clarithromycin for 8 weeks. Determi-
nation of blood and sputum eosinophil counts, sputum
eosinophil cationic protein (ECP) levels, and metha-
choline challenge testing were carried out before and after
treatment. At the conclusion of the study, all inflamma-
tory indices and values of PC20 for methacholine
improved. In a study of 11 patients with mild asthma, 250
mg azithromycin orally given twice weekly for 8 weeks
increased PC20 of methacholine significantly while FEV1
and FVC did not change [22].
Tamaoki and his colleagues [23] showed that erythromy-
cin, roxithromycin, and erythromycin attenuated the con-
tractile response of human isolated bronchial strips to
electrical field stimulation. Macrolide antibiotics may also
improve sputum quality and favorably impact secretion
clearance in asthma. Rubin and his colleagues [24]
showed that treatment with clarithromycin for two weeks
improved nasal secretion rheology, hydration, cohesion
and transportability in patients with purulent rhinitis.
Clarithromycin reduced mucus volume in both patients
and healthy individuals.
Persistent airway infection in asthma and 
macrolide antibiotics
One possible explanation for the efficacy of low-dose,
long-term macrolide antibiotics therapy in patients with
asthma is the putative role played by persistent airway
infections in its pathogenesis, particularly Chlamydia pneu-
moniae  and  Mycoplasma pneumoniae infections [25,26].
These infectious agents may underlie acute asthma exacer-
bations and the initiation and maintenance of asthma in
previously asymptomatic patients [27]. Infection with
Mycoplasma pneumoniae induces RANTES expression in
cultured human airway epithelial cell, an effect that is mit-
igated with erythromycin [28].
In a randomized double-blind placebo-controlled trial,
Kraft and her colleagues [29] studied the effects of low-
dose clarithromycin on 52 patients with stable asthma.
Patients had baseline spirometry, bronchoscopy with lav-
age and biopsy for PCR testing for infection with Chlamy-
dia pneumoniae and  Mycoplasma pneumoniae and
measurement of various inflammatory mediators
obtained from the lower respiratory tract. After 6 weeks of
treatment with clarithromycin, lung function (FEV1) sig-
nificantly improved but only in the group of patients with
evidence of infection. There were also significant reduc-
tions in levels of IL-5, IL-12, TNF-α in bronchoalveolar
lavage fluid and level of TNF-α in airway tissue in patients
with infection. Notably, there was a decrease in TNF-α
level in lavage fluid and airway tissue in patients without
evidence of infection as well.
These findings were also supported by Black and his col-
leagues [30] who found that patients with asthma and
serological evidence of infection with Chlamydia pneumo-
niae showed improvement in peak expiratory flow rates
after a 3-month course of roxithromycin. Intriguingly, the
authors also noted that the benefits seemed to diminish at
subsequent 3 month and 6 month time points following
therapy. They postulated that this was related, in part, to
lack of power of the study to detect a difference or failure
to eradicate the organisms. Alternatively, the immu-
nomodulatory effects of roxithromycin may have been
lost once the drug was stopped. A similar phenomenon
was reported in patients with diffuse panbronchiolitis in
Japan.
Conclusions
Low-dose, long-term 14- and 15-membered ring mac-
rolide antibiotic therapy represents a promising addition
to our anti-asthma drug armamentarium. The salutary
effects of these drugs are related, most likely, to their dis-
tinct immunomodulatory properties although eradica-
tion of persistent airway infection with Chlamydia
pneumoniae and Mycoplasma pneumoniae in patients with
asthma may also play a role. Clearly, additional, multi-
center, randomized, double-blind, placebo-controlled tri-
als are indicated to address these issues.
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